Frovatriptan Succinate Monohydrate causes vasoconstriction of arteries and veins that supply blood to the head. It is a triptan drug developed by Vernalis for the treatment of migraine headaches, in particular those associated with menstruation. Reference standards of Frovatriptan Succinate Monohydrate API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
Frovatriptan Succinate Monohydrate
Catalogue No.:PA 06 83000
CAS :
Molecular Formula : C18H25N3O6
Molecular Weight : 379.41
(S)-Frovatriptan
Catalogue No.:PA 06 83520
Molecular Formula : C14H17N3O
Molecular Weight : 243.3
(1R,3S)-1-Hydroxy-3-(methylamino)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamide
Catalogue No.:PA 06 83530
Molecular Formula : C14H17N3O2
Molecular Weight : 259.3
4-Hydroxy-frovatriptan
Catalogue No.:PA 06 83540
(1S,3S)-1-Hydroxy-3-(methylamino)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamide
Catalogue No.:PA 06 83550
3-Amino-1-methyl-5H-pyrido[4,3-b]indole Acetate
Catalogue No.:PA 06 83560
Molecular Formula : C14H15N3O2
Molecular Weight : 257.29
(R)-3-Amino-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamide
Catalogue No.:PA 06 0831000
Molecular Formula : C13H15N3O
Molecular Weight : 229.28
6-Amino-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide Hydrochloride
Catalogue No.:PA 06 0831001
Molecular Formula : C13H16ClN3O
Molecular Weight : 265.74
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....
